DexCom, Inc. $DXCM Shares Purchased by Retirement Systems of Alabama

Retirement Systems of Alabama lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 565.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 539,049 shares of the medical device company’s stock after purchasing an additional 457,986 shares during the period. Retirement Systems of Alabama owned about 0.14% of DexCom worth $46,515,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after acquiring an additional 1,515,702 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of DexCom in the 2nd quarter worth approximately $173,237,000. Janus Henderson Group PLC raised its holdings in shares of DexCom by 32.3% in the 1st quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company’s stock worth $166,077,000 after purchasing an additional 645,534 shares during the period. Deutsche Bank AG purchased a new position in DexCom in the second quarter valued at approximately $164,035,000. Finally, Arrowstreet Capital Limited Partnership lifted its stake in DexCom by 100.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock valued at $159,832,000 after purchasing an additional 1,275,142 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Sanford C. Bernstein increased their price objective on DexCom from $77.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Rothschild & Co Redburn raised their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Evercore boosted their target price on DexCom from $90.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. upped their price target on DexCom from $82.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 30th. Finally, Weiss Ratings upgraded DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Buy” and an average target price of $95.50.

Insider Buying and Selling at DexCom

In related news, Director Nicholas Augustinos sold 6,539 shares of DexCom stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $549,537.56. Following the completion of the transaction, the director directly owned 29,293 shares in the company, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president directly owned 146,828 shares in the company, valued at $12,226,367.56. The trade was a 2.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,822 shares of company stock valued at $1,920,193 over the last 90 days. 0.28% of the stock is currently owned by corporate insiders.

DexCom Price Performance

DXCM opened at $79.92 on Wednesday. The company has a market capitalization of $29.81 billion, a price-to-earnings ratio of 31.34, a PEG ratio of 1.34 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The firm has a 50-day moving average price of $84.79 and a 200-day moving average price of $75.08. DexCom, Inc. has a twelve month low of $55.84 and a twelve month high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 earnings per share. Equities analysts expect that DexCom, Inc. will post 2.68 EPS for the current year.

DexCom Company Profile

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.